Journal of child and adolescent psychopharmacology
-
J Child Adolesc Psychopharmacol · Jun 2009
Multicenter Study Controlled Clinical TrialLong-term safety and efficacy of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder.
Short-term, controlled studies of extended-release guanfacine (GXR), a selective alpha(2A)-adrenoreceptor agonist, demonstrate efficacy in treating attention-deficit/hyperactivity disorder (ADHD) symptoms as monotherapy. This 2-year open-label study was conducted to further assess the long-term safety and efficacy of GXR. ⋯ Overall, these data support that GXR monotherapy is generally safe and effective for treating ADHD.